bluuebunny/crossref_metadata_2025_split huggingface dataset:
Pressure-temperature-time evolution of the Milin pelitic schists: Implications for the tectonic evolution of the eastern Indus-Yarlung suture zone, eastern Himalaya
Authors: Li Wangchao , Yin Changqing , Yakymchuk Chris , Ding Lin , Li Shun , Qian Jiahui , Gao Peng , Zhang Yanling 
Published: April 2024

Abstract
We report an integrated comprehensive dataset composed of petrography, pressure-temperature (P-T) calculations, monazite U-Th-Pb ages, and trace-element data from pelitic schists in the eastern Indus-Yarlung suture zone in the Milin area of the eastern Himalaya. These rocks represent the exposure of subduction-related rocks within the eastern Indus-Yarlung suture zone accretionary complex. The dominant mineral assemblages of the pelitic schists are garnet + kyanite + staurolite + biotite + quartz and garnet + kyanite + staurolite + biotite + paragonite + sillimanite with quartz, plagioclase, and ilmenite assemblages. Phase equilibrium modeling of sillimanite-bearing pelitic schists yielded peak P-T conditions of ~670–680 °C at ~8.6 kbar, similar to that of kyanite-bearing schists (~670 °C, ~8.8 kbar). Monazite grains with complex internal structures retained variable ages ranging from 28 Ma to 15 Ma, which correlate systematically with changes in the concentrations of Y, Th, U, and heavy rare earth elements and ratios of Th/U. Combined with petrologic analysis, we conclude that the pelitic schists experienced a long-lived prograde metamorphism from ca. 28 Ma to ca. 22 Ma. Peak metamorphism occurred in the period 22–21 Ma, followed by quasi-isothermal decompression until 15 Ma. The discrepancies among metamorphic P-T-t paths in the eastern Indus-Yarlung suture zone indicate the presence of not only collision-related regional metamorphism at medium P-T conditions, but also subduction-related high-pressure–low-temperature terranes in the Milin region. These two domains experienced different P-T evolution and tectonic histories and were juxtaposed in the early Neogene during the India-Asia continental collision.
Clinical guidelines for children and adolescents experiencing gender dysphoria or incongruence: a systematic review of recommendations (part 2)
Authors: Taylor Jo , Hall Ruth , Heathcote Claire , Hewitt Catherine Elizabeth , Langton Trilby , Fraser Lorna 
Published: April 2024

BackgroundIncreasing numbers of children and adolescents experiencing gender dysphoria/incongruence are being referred to specialist gender services and there are various published guidelines outlining approaches to clinical care.AimTo examine the recommendations about the management of children and/or adolescents (age 0-18) experiencing gender dysphoria/incongruence in published guidelines or clinical guidance. A separate paper examines the quality and development of guidelines.MethodsA systematic review and narrative synthesis. Databases (Medline, Embase, CINAHL, PsycINFO, Web of Science) were searched to April 2022 and web-based searches and contact with international experts continued to December 2022, with results assessed independently by two reviewers. The Appraisal of Guidelines for Research and Evaluation tool was used to examine guideline quality.Results23 guidelines/clinical guidance publications (1998–2022) were identified (4 international, 3 regional, 16 national). Guidelines describe a similar care pathway starting with psychosocial care for prepubertal children, puberty suppressants followed by hormones for eligible adolescents and surgical interventions as these adolescents enter adulthood. In general, there is consensus that adolescents should receive a multidisciplinary assessment, although clear guidance about the purpose or approach is lacking. There are differing recommendations about when and on what basis psychological and medical interventions should be offered. There is limited guidance about what psychological care should be provided, about the management of prepubertal children or those with a non-binary gender identity, nor about pathways between specialist gender services and other providers.ConclusionsPublished guidance describes a similar care pathway; however, there is no current consensus about the purpose and process of assessment for children or adolescents with gender dysphoria/incongruence, or about when psychological or hormonal interventions should be offered and on what basis.PROSPERO registration numberCRD42021289659.
The 11+ injury prevention programme decreases rate of hamstring strain injuries in male collegiate soccer players
Authors: Silvers-Granelli Holly , Silverman Richard , Bizzini Mario , Thorborg Kristian , Brophy Robert H 
Published: April 2024

ObjectivesTo investigate if the 11+ injury prevention programme decreases the risk of hamstring injury and improves recovery time and determine whether compliance with the 11+ affects hamstring injury risk.MethodsThis study is a secondary analysis from a prospective cluster randomised controlled trial that included 65 National Collegiate Athletic Association (NCAA) division I and II men’s soccer teams over the fall 2012 season. Thirty-one teams were randomised to the intervention group that were using the 11+ as their warm-up and 35 teams to the control group that continued to use their traditional warm-up. Each certified athletic trainer (ATC) collected data on demographics, hamstring injury (HSI), mechanism of injury, position, playing surface, time lost due to injury and compliance to the 11+ programme.ResultsThe 11+ decreased the risk of HSI by 63% compared with the control group (RR=0.37, 95% CI 0.21 to 0.63). Difference in return to play after HSI between the control (9.4±11.2 days) and intervention groups (10.2±11.3 days) was not significant (p=0.8). High compliance (>2 or more doses on average per week) reduced the risk of HSI by 78% (RR=0.22, 95% CI 0.06 to 0.87) compared with low compliance (<1 dose on average per week), and moderate compliance (1 to <2 doses on average per week) decreased the risk of HSI by 67% (RR=0.33, 95% CI 0.11 to 0.97) compared with low compliance. There was no significant difference between high and moderate compliance.ConclusionThe 11+ decreased the risk of HSI by 63% but did not improve recovery time. High to moderate compliance is essential and makes the programme more effective at reducing HSI.
Adherence to pharmacological therapy in patients with hypertension: protocol of a qualitative study by focus groups
Authors: Rosendo-Silva Beatriz , Prazeres Filipe , Santiago Luiz Miguel , Rosendo Inês 
Published: April 2024

IntroductionNon-adherence to antihypertensive medication significantly contributes to inadequate blood pressure control. Regarding non-pharmacological interventions to improve medication adherence, the question remains of which interventions yield the highest efficacy.Understanding the complementary perspectives of patients and healthcare professionals can be valuable for designing strategies to enhance medication adherence. Few studies explored the perspectives of patients and healthcare professionals regarding medication adherence. None of them focused specifically on adherence to pharmacological therapy for hypertension in Portugal.Considering the high prevalence of non-adherence and its location-specific aspects, the priority should be identifying its barriers and developing tactics to address them.This study aims to gather the perspectives of patients with hypertension and healthcare professionals such as family doctors, nurses and community pharmacists from Portugal, regarding the most effective strategies to enhance antihypertensive medication adherence and to understand the factors contributing to non-adherence.Methods and analysesWe will conduct qualitative research through synchronous online focus groups of 6–10 participants. Some groups will involve patients with hypertension, while others will include family doctors, nurses and community pharmacists. The number of focus groups will depend on the achievement of theoretical saturation. A purposive sample will be used. Healthcare participants will be recruited via email, while patients will be recruited through their family doctors.The moderator will maintain neutrality while ensuring interactive contributions from every participant. Participants will be encouraged to express their opinions on the meeting summary. Meetings will be recorded and transcribed.Two researchers will perform content analyses usingMAXQDA V.12through comparative analyses and subsequent consensus. A third researcher will review the analyses. The results will be presented narratively.Ethics and disseminationThe Ethics Committee of the University of Coimbra has approved this study with the number: CE-026/2021. The results will be disseminated via peer-reviewed publications and national and international conferences.
Shanghai Community-Based Schizophrenia Cohort (SCS): a protocol for establishing a longitudinal cohort and research database of patients with schizophrenia receiving community-based mental health treatment
Authors: Zhu Youwei , He Siyuan , Liu Yanli , Chen Chunmei , Ge Xiaolei , Zhang Weibo , Zhu Yi , Zhou Qing , Jiang Yihua , Zhang Yanping , Xu Weiyun , Wang Na , Cai Jun , Xie Bin 
Published: April 2024

IntroductionDrivers for remission, relapse and violence-related behaviour among patients with schizophrenia are the most complicated issue.Methods and analysisThis study aims to recruit a longitudinal cohort of patients with schizophrenia. Two suburban districts and two urban districts were randomly selected according to health service facilities, population, geographical region and socioeconomic status. Individuals (>18 years old) who received a diagnosis of schizophrenia following the International Classification of Diseases (10th edition) criteria within the past 3 years will be invited as participants. Assessments will be carried out in local community health centres. Data will be used to (1) establish a community-based schizophrenia cohort and biobank, (2) prospectively determine the course of multidimensional functional outcomes of patients with schizophrenia who are receiving community-based mental health treatment, and (3) map the trajectories of patients with schizophrenia and prospectively determine the course of multidimensional outcomes based on the differential impact of potentially modifiable moderators.Ethics and disseminationThe study has been reviewed and approved by the Human Research Ethics Committee of Shanghai Mental Health Center (2021-67). Results of the study will be disseminated through peer-reviewed journals. If effective, related educational materials will be released to the public.
Association of maternal weight gain in early pregnancy with congenital heart disease in offspring: a China birth cohort study
Authors: Wang Jingjing , Zhang Simin , Li Xiaofei , Han Jijing , Sun Lijuan , Wang Li , Wu Qingqing 
Published: April 2024

ObjectivesLittle study has reported the association of maternal weight gain in early pregnancy with fetal congenital heart disease (CHD). We aimed to explore the potential relationship based on a China birth cohort while adjusting by multiple factors.DesignCohort study.SettingChina birth cohort study conducted from 2017 to 2021.ParticipantsThe study finally included 114 672 singleton pregnancies in the 6–14 weeks of gestation, without missing data or outliers, loss to follow-up or abnormal conditions other than CHD. The proportion of CHD was 0.65% (749 cases).Primary and secondary outcome measuresAssociation between maternal pre-pregnancy weight gain and CHD in the offspring were analysed by multivariate logistic regression, with the unadjusted, minimally adjusted and maximally adjusted methods, respectively.ResultsThe first-trimester weight gain showed similar discrimination of fetal CHD to that period of maternal body mass index (BMI) change (DeLong tests: p=0.091). Compared with weight gain in the lowest quartile (the weight gain less than 0.0 kg), the highest quartile (over 2.0 kg) was associated with a higher risk of fetal CHD in unadjusted (OR 1.36, 95% CI: 1.08 to 1.72), minimally adjusted (adjusted OR (aOR) 1.29, 95% CI: 1.02 to 1.62) and maximally adjusted (aOR 1.29, 95% CI: 1.02 to 1.63) models. The association remains robust in pregnant women with morning sickness, normal pre-pregnancy BMI, moderate physical activity, college/university level, natural conception or with folic acid (FA) and/or multivitamin supplementation.Conclusions and relevanceAlthough the association of maternal pre-pregnancy weight gain on fetal CHD is weak, the excessive weight gain may be a potential predictor of CHD in the offspring, especially in those with morning sickness and other conditions that are routine in the cohort, such as normal pre-pregnancy BMI, moderate physical activity, college/university level, natural conception or with FA and/or multivitamin supplementation.
Multifaceted pharmacist-led interventions in secondary care settings between countries of various income levels: a scoping review protocol
Authors: Tharmalinga Sharma Jegath Janani , McMillan Sara S , Samaranayake Nithushi R , Waas Dulshika A , Coombes Ian D , Wheeler Amanda J 
Published: April 2024

IntroductionClinical pharmacy services often involve multifaceted pharmacist-led interventions. However, current pharmacy practice models vary across different countries. Despite the documented benefits of clinical pharmacy services, the characteristics of pharmacist-led interventions in different countries have not yet been adequately explored and described. Therefore, this protocol outlines the methodology for a proposed scoping review aiming to investigate various types of multifaceted pharmacist-led interventions and the outcomes used to evaluate their effectiveness within secondary care settings. Additionally, the scoping review will map the current evidence surrounding the characteristics of interventions and outcomes reported across various countries of socioeconomic status.Methods and analysisThe scoping review will be conducted according to the JBI Methodology for Scoping Reviews and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Extension for Scoping Reviews. We will systematically search the following electronic databases: MEDLINE (Ovid), CINAHL (EbscoHost), Embase (embase.com), Scopus (scopus.com), Cochrane Library (cochranelibrary.com) and APA PsycInfo (Ovid). Additionally, the reference lists of identified reviews and included full texts will be searched for relevant papers. Grey literature sources, such as International Pharmaceutical Abstracts and the International Pharmaceutical Federation (FIP) website, will be searched. We will include primary studies published in the English language from January 2013 to December 2023, involving secondary care multifaceted pharmacist-led interventions. Two independent reviewers will screen studies against eligibility criteria and use a piloted data extraction form to extract relevant information. We will extract relevant data, complete a tabular summary from each included publication and analyse it.Ethics and disseminationEthical approval is not required as we will be using data from publicly available literature sources. Findings will be disseminated in publications and presentations with relevant stakeholders. We aim to map available evidence across the breadth of studies that have reported multifaceted pharmacist-led interventions and their outcomes.
Rationality of the FIGO2023 staging for early-stage endometrial cancer, compared with the FIGO2009 staging
Authors: Zhu Aoxuan , Dong Yangyang , Li Xingchen , Wang Yiqin , Wang Jianliu 
Published: April 2024

ObjectiveThe International Federation of Gynecology and Obstetrics (FIGO) released a new staging for endometrial cancer (EC), which revised the FIGO2009 staging to include histopathological and molecular features. The purpose of this study was to validate the prognostic accuracy of the new staging and discuss its clinical applicability.MethodsIn this single-centre retrospective study, 540 patients with primary surgically treated early-stage EC were enrolled and staged according to FIGO2009/2023. Kaplan-Meier survival analysis was used to compare for prognostic differentiation. Cox regression was used to identify potential prognostic indicators.ResultsA total of 81 patients underwent staging shifts, all stage elevation. The prognosis difference between new stages I and II was more significant. The new staging was more predictive of death postoperatively. Lesion maximum diameter (LMD) was one of the independent risk factors associated with prognosis. Taking LMD=5.70 cm as the cut-off value could further differentiate patients with divergent prognoses within FIGO2023 stage IIC.ConclusionFIGO2023 staging demonstrated greater prognostic accuracy. In addition, LMD may be another critical factor affecting prognosis.
Intertwined depressive and cognitive trajectories and the risk of dementia and death in older adults: a competing risk analysis
Authors: Ren Ziyang , Nie Lirong , Du Yushan , Liu Jufen 
Published: April 2024

BackgroundDepressive symptoms and cognitive impairment often interact, rendering their associations controversial. To date, their joint trajectories and associations with dementia and death remain underexplored.AimsTo explore the interactions between depressive symptoms and cognitive function, their developmental trajectories and the associations with all-cause dementia, Alzheimer’s disease (AD) and all-cause death in older adults.MethodsData were from the Health and Retirement Study. Depressive symptoms and cognitive function were measured using the 8-item Centre for Epidemiologic Studies Depression Scale and the Telephone Interview of Cognitive Status, respectively. All-cause dementia and AD were defined by self-reported or proxy-reported physician diagnoses. All-cause death was determined by interviews. The restricted cubic spline, group-based trajectory modelling and subdistribution hazard regression were used.ResultsSignificant interactions between depressive symptoms and cognitive function in 2010 in their association with new-onset all-cause dementia and AD from 2010 to 2020 were found, especially in women (p for interaction <0.05). Independent trajectory analysis showed that emerging or high (vs no) depressive trajectories and poor or rapidly decreased cognitive trajectories (vs very good) from 1996 to 2010 were at significantly higher risk of subsequent all-cause dementia, AD and all-cause death. 15 joint trajectories of depressive symptoms and cognitive function from 1996 to 2010 were determined, where rapidly decreased cognitive function was more common in those with no depressive symptoms. Compared with older adults with the trajectory of no depressive symptoms and very good cognitive function, those with the trajectory of no depressive symptoms but rapidly decreased cognitive function were much more likely to develop new-onset all-cause dementia and death, with subdistribution hazard ratios (95% confidence intervals) of 4.47 (2.99 to 6.67) and 1.84 (1.43 to 2.36), especially in women.ConclusionsTo effectively mitigate the risk of dementia and death, it is crucial to acknowledge the importance of preventing cognitive decline in older adults without depressive symptoms, particularly in women.
Associations between life course longitudinal growth and hip shapes at ages 60–64 years: evidence from the MRC National Survey of Health and Development
Authors: Staines Katherine Ann , Saunders Fiona R , Ireland Alex , Aspden Richard M , Gregory Jennifer S , Hardy Rebecca J , Cooper Rachel 
Published: April 2024

ObjectiveWe sought to examine associations between height gain across childhood and adolescence with hip shape in individuals aged 60–64 years from the Medical Research Council National Survey of Health and Development, a nationally representative British birth cohort.MethodsHeight was measured at ages 2, 4, 6, 7, 11 and 15 years, and self-reported at age 20 years. 10 modes of variation in hip shape (HM1–10), described by statistical shape models, were previously ascertained from DXA images taken at ages 60–64 years. Associations between (1) height at each age; (2) Super-Imposition by Translation And Rotation (SITAR) growth curve variables of height size, tempo and velocity; and (3) height gain during specific periods of childhood and adolescence, and HM1–10 were tested.ResultsFaster growth velocity was associated with a wider, flatter femoral head and neck, as described by positive scores for HM6 (regression coefficient 0.014; 95% CI 0.08 to 0.019; p<0.001) and HM7 (regression coefficient 0.07; 95% CI 0.002 to 0.013; p=0.009), and negative scores for HM10 (regression coefficient −0.006; 95% CI −0.011 to 0.00, p=0.04) and HM2 (males only, regression coefficient −0.017; 95% CI −0.026 to −0.09; p<0.001). Similar associations were observed with greater height size and later height tempo. Examination of height gains during specific periods of childhood and adolescence identified those during the adolescence period as being most consistently associated.ConclusionOur analyses suggest that individual growth patterns, particularly in the adolescent period, are associated with modest variations in hip shape at 60–64 years, which are consistent with features seen in osteoarthritis.
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test
Authors: Di Matteo Andrea , Mankia Kulveer , Garcia-Montoya Leticia , Sharrack Sana , Duquenne Laurence , Nam Jacqueline L , Mahler Michael , Emery Paul 
Published: April 2024

ObjectivesTo investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) in individuals with new musculoskeletal (MSK) symptoms and a negative second-generation anti-CCP antibody test (anti-CCP2−).Methods469 anti-CCP2− individuals underwent baseline anti-CCP3 testing (QUANTA Lite CCP3; Inova Diagnostics) and received a post enrolment 12-month questionnaire. A rheumatologist confirmed or excluded diagnosis of IA. Univariable/multivariable analyses were performed to assess the value of anti-CCP3 in predicting IA development in these anti-CCP2− individuals.ResultsOnly 16/469 (3.4%) anti-CCP2− individuals had a positive anti-CCP3 test. Of these 16 individuals, 4 developed IA. In addition, 61/469 (13.0%) anti-CCP2− individuals self-reported, to have developed, IA. Progression was confirmed in 43/61 of them (70.5%); of whom 30/43 (69.8%) and 13/43 (30.2%) were given a diagnosis of IA and rheumatoid arthritis (RA), respectively. In qualitative univariable analysis, anti-CCP3 positivity was associated with self-reported progression (p<0.01) and IA (p=0.03), but not with RA. Anti-CCP3 levels differed significantly between progressors and non-progressors (p<0.01) for all three categories. At the manufacturer’s cut-off, OR for progression ranged from 2.4 (95% CI 0.5 to 18.6; RA) to 7.5 (95% CI 2.3 to 24.0; self-reported progression). Interestingly, when cut-offs for anti-CCP3 were optimised, lower values (≥5 units) significantly increased the OR for progression in all three categories. In multivariable analysis, anti-CCP3 positivity at the manufacturer’s cut-off did not remain associated with IA progression, while this lower cut-off value (≥5 units) was associated with diagnosis of RA (p=0.02).ConclusionsAnti-CCP3 testing could improve the prediction of IA development in anti-CCP2− individuals with new MSK symptoms.